|
|||||||||||||||||||||||||||||||||
|
Datum: 05.05.2010 Uhrzeit: 10:00 Proteomics: From Technologies to Targets and Biomarkers Workshop VI Workshop VI Proteomics:
From Technologies to Targets and Biomarkers Programme: Moving Closer – Biomarker and Imaging for Drug Development & Safety, Diagnosis and Treatment of DiseasesDr. Oliver Steinbach, Department Head Bio-Molecular Engineering, Philips Research Laboratories, Eindhoven, The Netherlands An integrative genome-based approach to the study of sepsis Hamid Hossain, PhD, Justus Liebig University of Giessen, Giessen, Germany A quantitative chemical proteomics approach reveals novel modes of action of clinical ABL kinase inhibitors Prof. Dr. Bernhard Küster, Chair of Biological Chemistry, Technische Universität München (TUM), Freising-Weihenstephan, Germany Translating a Biomarker from early Discovery into the Clinics: What does it Take? PD Dr. Hanno Langen, Global Head of Protein and Metabolite Biomarker Technologies, Molecular Medicine Laboraties, F.Hoffmann-La Roche, Basel, Switzerland Development and Validation of Biomarker Panels in NeuroPsychiatry Michael Spain, M.D. | Chief Medical Officer, Rules-Based Medicine (RBM), Austin, TX, USA From arrays towards fighting the tuberculosis epidemic Dr. Gerd Michel, Senior Technology Officer, FIND - Foundation for Innovative New Diagnostics, 71 avenue Louis Casai, 1216 Cointrin/Geneva, Switzerland Unlocking the serum proteome for clinical applications Prof. Carl A.K. Borrebaeck, Department of Immunotechnology, Lund University, Sweden Miniaturized immunoassays – technologies & applications Thomas Joos PhD, NMI Natural and Medical Sciences Institute at the University of Tübingen, Markwiesenstr. 55, 72770 Reutlingen, Germany |
||
|
| |||
 |
|||